Eight biotech firms are developing innovative therapies for breast cancer. Arvinas employs targeted protein degradation to tackle disease-causing proteins, while BioNTech uses mRNA-based therapies, antibodies and a small molecule immunomodulator to create individualized treatment options. Other methods being developed include ONA-XR, a selective antagonist of the progesterone receptor by Context Therapeutics, and an immuno-oncolytic virus being studied by Oncolytics Biotech. Meanwhile, Hummingbird Bioscience is focusing on Human Epidermal Growth Factor Receptor 3. These approaches could provide much-needed new treatments for breast cancer patients.
China-Linked UAT-8302 Targets Governments Using Shared APT Malware Across Regions – The Hacker News
China-Linked UAT-8302 Targets Governments Using Shared APT Malware Across Regions The Hacker News
.webp?w=0&resize=0,0&ssl=1 "Education Sector Under Attack From State Espionage, Spear-Phishing, and Supply Chain Attacks")
